Session Information
Date: Saturday, November 16, 2024
Title: SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I
Session Type: Poster Session A
Session Time: 10:30AM-12:30PM
Background/Purpose: Interleukin 40 (IL-40) is a novel cytokine with a proposed role in the pathogenesis of inflammatory diseases. Inflammatory bowel diseases (IBD)-associated with spondyloarthritis (SpA) are group of chronic immune-mediated inflammatory diseases that significantly affect patients’ quality of life. Understanding the pro-inflammatory mechanisms underlying this association for gaining insight into its nature, facilitating early diagnosis, and recognizing SpA in IBD patients. Furthermore, studies in mice have identified a link between IL-40 expression and the gut microbiome. Thus, we aimed to analyse the implication of IL-40 in SpA-IBD.
Methods: A cohort of 29 patients with SpA-IBD, 20 patients with IBD and 52 healthy controls (HC) was selected for the purpose of this preliminary study. The levels of IL-40 were measured using a commercially available ELISA kit. Inclusion criteria for patients involved meeting the modified New York criteria or Assessment of SpondyloArthritis International Society (ASAS) classification for SpA and fulfilling clinical, radiological, histological and/or endoscopic criteria for IBD. Disease activity was determined using C-reactive protein (CRP) and serum calprotectin levels. For IBD patients, clinical activity was assessed using the Harvey Bradshaw Index/Total Mayo score, and endoscopic activity was measured using the Simple Endoscopic Score for Crohn’s Diseases/Mayo score.
Results: Serum IL-40 levels were significantly higher in patients with IBD compared to those with SpA-IBD and HC [3.89 (1.92-5.85) vs. 2.30 (1.14-3.29) and 1.85 (1.17-2.67) ng/ml; p< 0.01 and p< 0.0001, respectively]. Additionally, we found association between IL-40 levels and serum CRP (r=0.481, p=0.032), serum calprotectin (r=0.473, p=0.035), and intestinal score activity (r=0.508, p=0.022). Additionally, there was a trend for correlation between IL-40 levels and the Total Mayo score – DAI in patients with ulcerative colitis (r=0.521, p=0.070). While the elevation of IL-40 in the serum of SpA-IBD patients did not reach significance compared to HC; we observed a negative correlation of IL-40 with the components of spinal mobility such as Schober (r=-0.515, p=0.004), chest expansion (r=-0.466, p=0.011), and positive correlation with distance chin-sternum (r=0.407, p=0.029). Patients with enthesitis tended to have higher levels of IL-40 compared to those without enthesitis (p=0.08). Furthermore, SpA-IBD patients with higher levels of IL-40 (cut-off 2.5 ng/ml) exhibited increased parameters of systemic inflammation, including ESR (p=0.02) and CRP (p=0.09).
Conclusion: We demonstrated that serum cytokine IL-40 shows potential associations with pro-inflammatory activity in IBD and SpA. This work was supported by Ministry of health Czech Republic [NU21-05-00276, 023728]; Ministry of Education, Youth and Sports Czech Republic [SVV-260638] and BBMRI. cz, reg.no. [LM2023033].
To cite this abstract in AMA style:
Ondrejčáková L, Navrátilová A, Gregová M, Bubová K, Grega T, Šenolt L, Pavelka K, Andrés Cerezo L. Serum Interleukin IL-40 as a Potential Biomarker Associated with Pro-inflammatory Activity in Inflammatory Bowel Diseases and Spondyloarthritis: A Preliminary Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/serum-interleukin-il-40-as-a-potential-biomarker-associated-with-pro-inflammatory-activity-in-inflammatory-bowel-diseases-and-spondyloarthritis-a-preliminary-study/. Accessed .« Back to ACR Convergence 2024
ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-interleukin-il-40-as-a-potential-biomarker-associated-with-pro-inflammatory-activity-in-inflammatory-bowel-diseases-and-spondyloarthritis-a-preliminary-study/